- Home
- QNRX vs PLRZ Comparison
QNRX vs PLRZ Comparison
Compare QNRX & PLRZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- PLRZ
- Stock Information
- Founded
- QNRX 2018
- PLRZ 2005
- Country
- QNRX United States
- PLRZ Israel
- Employees
- QNRX N/A
- PLRZ N/A
- Industry
- QNRX Medical/Dental Instruments
- PLRZ
- Sector
- QNRX Health Care
- PLRZ
- Exchange
- QNRX Nasdaq
- PLRZ NYSE
- Market Cap
- QNRX 3.3M
- PLRZ 14.7M
- IPO Year
- QNRX N/A
- PLRZ 2024
- Fundamental
- Price
- QNRX $6.26
- PLRZ $0.59
- Analyst Decision
- QNRX
- PLRZ
- Analyst Count
- QNRX 0
- PLRZ 0
- Target Price
- QNRX N/A
- PLRZ N/A
- AVG Volume (30 Days)
- QNRX 44.8K
- PLRZ 20.3M
- Earning Date
- QNRX 05-13-2025
- PLRZ 02-15-2025
- Dividend Yield
- QNRX N/A
- PLRZ N/A
- EPS Growth
- QNRX N/A
- PLRZ N/A
- EPS
- QNRX N/A
- PLRZ N/A
- Revenue
- QNRX N/A
- PLRZ N/A
- Revenue This Year
- QNRX N/A
- PLRZ N/A
- Revenue Next Year
- QNRX N/A
- PLRZ N/A
- P/E Ratio
- QNRX N/A
- PLRZ N/A
- Revenue Growth
- QNRX N/A
- PLRZ N/A
- 52 Week Low
- QNRX $5.01
- PLRZ $0.25
- 52 Week High
- QNRX $54.95
- PLRZ $4.80
- Technical
- Relative Strength Index (RSI)
- QNRX 42.24
- PLRZ N/A
- Support Level
- QNRX $6.05
- PLRZ N/A
- Resistance Level
- QNRX $7.09
- PLRZ N/A
- Average True Range (ATR)
- QNRX 0.74
- PLRZ 0.00
- MACD
- QNRX 0.15
- PLRZ 0.00
- Stochastic Oscillator
- QNRX 41.50
- PLRZ 0.00
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About PLRZ POLYRIZON LTD
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.